Florit E A, Bennis S, Rodriguez E, Revuelta I, De Sousa E, Esforzado N, Cofán F, Ricart M J, Torregrosa J V, Campistol J M, Oppenheimer F, Diekmann F
Servicio de Nefrología - Clinical Institute of Nephrology and Urology, Hospital Clinic, Barcelona, Spain.
Servicio de Nefrología - Clinical Institute of Nephrology and Urology, Hospital Clinic, Barcelona, Spain.
Transplant Proc. 2015 Oct;47(8):2351-3. doi: 10.1016/j.transproceed.2015.09.003.
The aim of this study was to compare the group of patients receiving a new kidney transplant before starting dialysis again (pre-reTR) with a group of patients receiving a new kidney transplant after restarting dialysis (reTR).
This retrospective cohort included all the kidney retransplantations (second transplantations) between 2000 and 2012 performed at our center and their follow-up until July 2014. We analysed graft and patient survival, rejection rates, and immunologic parameters of these patients.
We studied 18 patients who had pre-reTR and 83 who had reTR. In the pre-reTR group no patient had panel-reactive assay (PRA) >10% at any time. In the reTR group 26.5% had PRA >10% at the time of transplantation (P = .014) and 54.2% had a historical highest PRA >10% (P < .001). The rejection rate was 11.1% in the pre-reTR group and 27.7% in the reTR group during the first year post-retransplantation (P = .227). Patient survival rate was 100% in the pre-reTR group at 5 years of follow-up, whereas in the reTR group at 1 year it was 95.2% and 85.9% at 5 years after retransplantation. Allograft survival at 1 and 5 years was 88% and 89%, respectively, in the pre-reTR group. On the other hand, in the reTR group it was 89% after the first year and 65% at 5 years post-retransplantation.
Pre-emptive renal retransplantation is a feasible option that should be assessed in patients with kidney graft failure and may help to minimize the morbidity associated with dialysis reinitiation.
本研究的目的是比较在再次开始透析之前接受新肾移植的患者组(移植前重新移植组)与重新开始透析后接受新肾移植的患者组(移植后重新移植组)。
这项回顾性队列研究纳入了2000年至2012年在我们中心进行的所有肾再次移植(第二次移植)及其至2014年7月的随访情况。我们分析了这些患者的移植物和患者生存率、排斥率及免疫参数。
我们研究了18例移植前重新移植患者和83例移植后重新移植患者。在移植前重新移植组中,任何时候均无患者的群体反应性抗体检测(PRA)>10%。在移植后重新移植组中,26.5%的患者在移植时PRA>10%(P = 0.014),54.2%的患者既往最高PRA>10%(P < 0.001)。在再次移植后的第一年,移植前重新移植组的排斥率为11.1%,移植后重新移植组为27.7%(P = 0.227)。移植前重新移植组在随访5年时患者生存率为100%,而移植后重新移植组在再次移植后1年时为95.2%,5年时为85.9%。移植前重新移植组在1年和5年时的同种异体移植物生存率分别为88%和89%。另一方面,移植后重新移植组在第一年为89%,在再次移植后5年为65%。
抢先性肾再次移植是一种可行的选择,应在肾移植失败患者中进行评估,这可能有助于将与重新开始透析相关的发病率降至最低。